Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 7/20 | 0.94 |
| ▸ | P2RX1 | P51575 | 4/20 | 0.94 |
| ▸ | P2RX3 | P56373 | 4/20 | 0.94 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.94 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.94 |
| ▸ | SRC | P12931 | 2/20 | 0.94 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.94 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.94 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.94 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.88 |
| ▸ | TRPM2 | O94759 | 2/20 | 0.88 |
| ▸ | MACROD2 | A1Z1Q3 | 1/20 | 0.88 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.88 |
| ▸ | MACROD1 | Q9BQ69 | 1/20 | 0.88 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.83 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.83 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.83 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.83 |
| ▸ | LDHA | P00338 | 1/20 | 0.83 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9171542 | 1.00 | P2RY1 (0.94) | P2RY1P2RX1P2RX3P2RY2P2RX2 | |
| SCHEMBL376008 | 1.00 | P2RY1 (0.94) | P2RY1P2RX1P2RX3P2RY2P2RX2 | |
| Adenosine Triphosphate SCHEMBL8979 | 1.00 | P2RY1 (0.94) | P2RY1P2RX1P2RX3P2RY2P2RX2 | |
| Adenosine Triphosphate SCHEMBL6242713 | 1.00 | P2RY1 (0.94) | P2RY1P2RX1P2RX3P2RY2P2RX2 | |
| Adenosine Triphosphate SCHEMBL18784961 | 1.00 | P2RY1 (0.94) | P2RY1P2RX1P2RX3P2RY2P2RX2 | |
| Adenosine Triphosphate SCHEMBL13722152 | 1.00 | P2RY1 (0.94) | P2RY1P2RX1P2RX3P2RY2P2RX2 | |
| Adenosine Triphosphate SCHEMBL13722139 | 1.00 | P2RY1 (0.94) | P2RY1P2RX1P2RX3P2RY2P2RX2 | |
| Adenosine Triphosphate SCHEMBL2227081 | 1.00 | P2RY1 (0.94) | P2RY1P2RX1P2RX3P2RY2P2RX2 | |
| Adenosine Triphosphate SCHEMBL20550531 | 1.00 | P2RY1 (0.94) | P2RY1P2RX1P2RX3P2RY2P2RX2 | |
| Adenosine Triphosphate SCHEMBL8980 | 1.00 | P2RY1 (0.94) | P2RY1P2RX1P2RX3P2RY2P2RX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240240170-A1 | POLYANIONIC ACIDS TO IMPROVE RECOVERY AND MINIMIZE SYSTEM LOSS | WATERS TECHNOLOGIES CORPORATION (US) | 2024-07-18 | — | — | US | disclosed |
| US-11912983-B2 | Polyanionic acids to improve recovery and minimize system loss | WATERS TECHNOLOGIES CORPORATION (US) | 2024-02-27 | — | — | US | disclosed |
| US-11819550-B2 | Liquid protein formulations containing cyclic adenosine monophosphate (cAMP) or adenosine triphosphate (ATP) | EAGLE BIOLOGICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-20180153997-A1 | Liquid Protein Formulations Containing Organophosphates | EAGLE BIOLOGICS, INC. | 2018-06-07 | — | — | US | disclosed |
| US-9913905-B2 | Liquid pharmaceutical formulations for injection comprising thiamine pyrophosphate 1-(3-aminopropyl)-2-methyl-1H-imidazole and uses thereof | EAGLE BIOLOGICS, INC. (US) | 2018-03-13 | — | — | US | disclosed |
| US-20170363613-A1 | SIMULTANEOUS DETECTION OF CANNIBALISM AND SENESCENCE AS PROGNOSTIC MARKER FOR CANCER | INSTITUT GUSTAVE-ROUSSY (FR) | 2017-12-21 | — | — | US | disclosed |
| US-9726661-B2 | Simultaneous detection of cannibalism and senescence as prognostic marker for cancer | INSTITUT GUSTAVE-ROUSSY (FR) | 2017-08-08 | — | — | US | disclosed |
| WO-2017123072-A1 | NEW POLYPHOSPHATE-DEPENDENT GLUCOKINASE AND METHOD FOR PRODUCING GLUCOSE 6-PHOSPHATE USING SAME | 씨제이제일제당(주) | 2017-07-20 | — | — | WO | disclosed |
| US-20170112948-A1 | Inorganic-organic hybrid compound | Karlsruher Institut für Technologie (DE) | 2017-04-27 | — | — | US | disclosed |
| US-20160354491-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2016-12-08 | — | — | US | disclosed |
| US-20150185202-A1 | SIMULTANEOUS DETECTION OF CANNIBALISM AND SENESCENCE AS PROGNOSTIC MARKER FOR CANCER | INSTITUT GUSTAVE-ROUSSY (FR) | 2015-07-02 | — | — | US | disclosed |
| US-9006208-B2 | Agent for treatment of dry eye characterized by combining P2Y2 receptor agonist and hyaluronic acid or salt thereof, method for treating dry eye, and use of the P2Y2 receptor agonist and hyaluronic acid or salt thereof | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2015-04-14 | — | — | US | disclosed |
| US-9006208-B2 | Agent for treatment of dry eye characterized by combining P2Y2 receptor agonist and hyaluronic acid or salt thereof, method for treating dry eye, and use of the P2Y2 receptor agonist and hyaluronic acid or salt thereof | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2015-04-14 | — | — | US | disclosed |
| US-20150071921-A1 | LIQUID PROTEIN FORMULATIONS CONTAINING ORGANOPHOSPHATES | EAGLE BIOLOGICS, INC. | 2015-03-12 | — | — | US | disclosed |
| US-20150071921-A1 | LIQUID PROTEIN FORMULATIONS CONTAINING ORGANOPHOSPHATES | EAGLE BIOLOGICS, INC. | 2015-03-12 | — | — | US | disclosed |
| US-20140072559-A1 | Highly concentrated aqueous protein solution with reduced viscosity | ADOCIA (FR) | 2014-03-13 | — | — | US | disclosed |
| EP-2250247-B1 | COMPOSITION | RECKITT BENCKISER NV (NL) | 2014-03-12 | — | — | EP | disclosed |
| US-20130172287-A1 | AGENT FOR TREATMENT OF DRY EYE CHARACTERIZED BY COMBINING P2Y2 RECEPTOR AGONIST AND HYALURONIC ACID OR SALT THEREOF, METHOD FOR TREATING DRY EYE, AND USE OF THE P2Y2 RECEPTOR AGONIST AND HYALURONIC ACID OR SALT THEREOF | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2013-07-04 | — | — | US | disclosed |
| US-20110053819-A1 | Composition | RECKITT BENCKISER FINISH B.V. (NL) | 2011-03-03 | — | — | US | disclosed |
| US-7569558-B2 | Topical delivery of trace metals for skin care | BIODERM RESEARCH (US) | 2009-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140072559-A1 | Highly concentrated aqueous protein solution with reduced viscosity | DCTD, RNGTT, HNRNPUL2 | P2RY1 3278/4885P2RX1 4148/4885P2RX3 4412/4885 |
| US-11819550-B2 | Liquid protein formulations containing cyclic adenosine monophosphate (cAMP) or adenosine triphosphate (ATP) | PDE7A, PDE8A, PDE8B | P2RY1 82/4885P2RX1 155/4885P2RX3 172/4885 |
| US-20160354491-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | P2RY1 2661/4885P2RX1 3638/4885P2RX3 3314/4885 |
| US-20150071921-A1 | LIQUID PROTEIN FORMULATIONS CONTAINING ORGANOPHOSPHATES | IGFBP1, IGFBP5, IGF2BP1 | P2RY1 2607/4885P2RX1 2735/4885P2RX3 2600/4885 |
| US-20170112948-A1 | Inorganic-organic hybrid compound | SLCO4C1, SLCO2A1, SLCO1A2 | P2RY1 947/4885P2RX1 627/4885P2RX3 490/4885 |
| US-20130172287-A1 | AGENT FOR TREATMENT OF DRY EYE CHARACTERIZED BY COMBINING P2Y2 RECEPTOR AGONIST AND HYALURONIC ACID OR SALT THEREOF, METHOD FOR TREATING DRY EYE, AND USE OF THE P2Y2 RECEPTOR AGONIST AND HYALURONIC ACID OR SALT THEREOF | P2RY2, P2RY12, P2RY13 | P2RY1 5/4885P2RX1 20/4885P2RX3 32/4885 |
| US-20180153997-A1 | Liquid Protein Formulations Containing Organophosphates | IGFBP1, IGFBP5, IGF2BP1 | P2RY1 2607/4885P2RX1 2735/4885P2RX3 2600/4885 |
| US-20110053819-A1 | Composition | POLI, CPSF7, CPSF6 | P2RY1 872/4885P2RX1 1523/4885P2RX3 1569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.